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Background: Diabetic patients experience stimulated coagulation and dysfibrinolysis, which is associated with an
increased risk of cardiovascular events. This imbalance may precede the manifest diagnosis. We investigated
whether elevated antigen levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), the
tPA/PAI-1 complex, or von Willebrand Factor (VWF) precede type 2 diabetes mellitus (T2DM) diagnosis, and
whether this elevation occurs before increased fasting plasma glucose (FPG) or 2-hour plasma glucose (2hPG) in
individuals who later develop T2DM.
Methods: We conducted a prospective incident case-referent study within the Västerbotten Intervention
Programme. Cardiovascular risk factor data as well as FPG and 2hPG and blood samples for future research were
collected at a baseline health examination between 1989 and 2000, (n= 28 736). During follow-up in January 2001,
157 cases had developed T2DM. Referents without T2DM were matched for sex, age, and year of participation
(n=277). Subgroup analysis was performed for cases with normal baseline glucose levels (FPG <6.1 mmol/L and
2hPG < 8.9 mmol/L) and cases with elevated levels (FPG 6.1-6.9 mmol/L and/or 2hPG 8.9-12.1 mmol/L).
Results: After adjusting for BMI, family history of diabetes, physical activity, smoking, systolic blood pressure and
levels of C-reactive protein and triglycerides, independent associations were found between incident T2DM and
elevated levels of tPA (OR=1.54, 95% CI 1.06-2.23), PAI-1 (OR=1.61, 95% CI 1.14-2.28), and tPA/PAI-1 complex
(OR=2.45, 95% CI 1.56-3.84). In participants with normal glucose levels, PAI-1 (OR=2.06, 95% CI 1.10 - 3.86) exhibited
an independent relationship with incident T2DM after the adjustments.
Conclusions: Elevated levels of fibrinolytic variables precede the manifestation of T2DM after adjusting for
metabolic and cardiovascular risk factors and can be detected several years before changes in glucose tolerance.
Keywords: Diabetes mellitus type 2, Tissue plasminogen activator, Plasminogen activator inhibitor-1, Von
Willebrand factor, Fibrinolysis, Population study, Västerbotten Intervention ProgrammeBackground
Smoking [1], low physical activity [2], obesity, insulin re-
sistance, and hyperglycaemia [3] are independently asso-
ciated with incident type 2 diabetes mellitus (T2DM).
Insulin resistance is affected by metabolic risk factors for
both T2DM and cardiovascular disease, including overall
obesity, central obesity, elevated triglyceride levels, low* Correspondence: jenny.hernestal-boman@medicin.umu.se
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distribution, and reproduction in any mediumHDL levels, hyperglycaemia, and hypertension [4].
Hyperglycaemia has been shown to stimulate coagula-
tion in healthy humans, and hyperinsulinaemia has been
associated with impaired fibrinolysis [5]. Diabetic
patients have elevated levels of coagulation factors and
impaired fibrinolysis, inducing a hypercoagulable state
that may contribute to the increased risk of athero-
thrombotic events and venous thromboembolism [6-9].
Although reducing fasting plasma glucose levels to nor-
mal is seen as a way to prevent negative cardiovascular
outcomes, such as myocardial infarction or stroke [10],d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients failed to prove any protective effect of tight gly-
caemic control [11].
High levels of tPA have been shown to be predictive of
future T2DM independent from metabolic syndrome
[12,13]. Another study showed that tPA and PAI-1 levels
are similar in patients with newly diagnosed T2DM
compared to patients with T2DM for a long duration
[14]. These findings indicate that impaired fibrinolysis in
diabetic patients precedes the manifest diagnosis.
Some investigations have demonstrated that PAI-1 is
predictive of T2DM but that its predictive ability disap-
pears after adjusting for markers of metabolic syndrome
[15,16]. This observation suggests that high plasma PAI-
1 levels are associated with factors involved in metabolic
syndrome, mainly obesity [17]. Other studies have indi-
cated that high baseline PAI-1 levels are associated with
incident diabetes [18] and that PAI-1 levels continue to
increase with increasing glucose levels and the develop-
ment of T2DM [19,20]. The tPA/PAI-1 complex, tPA
bound to PAI-1, has been associated with cardiovascular
disease [21,22], but its relation to incident diabetes is
unknown.
Elevated von Willebrand Factor (VWF) levels increase
the risk of cardiovascular events in patients with T2DM
[23] but have not been shown to be associated with inci-
dent T2DM [13]. VWF is produced by endothelial cells,
which may be activated by proinflammatory cytokines
[24] such as IL-6, which in turn have been associated
with an increased risk of incident T2DM [25]. C-reactive
protein (CRP) has also been associated with an increased
risk of incident T2DM, though this association was lost
after adjusting for IL-6 [13].
To investigate the relationship between haemostatic
factors and incident T2DM, we used a prospective
population-based case-referent study. Our primary aim
was to investigate whether elevated antigen levels ofFigure 1 Schematic figure of study population.tPA, PAI-1, tPA/PAI-1 complex, and vWF precede the
diagnosis of T2DM. Our secondary aim was to study
whether these haemostatic variables increase prior to




We conducted a nested case-referent (case–control)
study within the Västerbotten Intervention Programme
(VIP) [26], a cardiovascular disease intervention project
(Figure 1). All patients in Västerbotten County in north-
ern Sweden were invited to participate in a health survey
at their local primary-care centre when they were 30, 40,
50, or 60 years of age. At the health examination, data
about age, sex, and cardiovascular risk factors were col-
lected. Participants were also asked to donate a blood
sample for research, which was stored at the Northern
Sweden Medical Research Bank. The participation rate
was high; the total study population from 1989 to 2000
represented 52% of the eligible population [27]. The vast
majority of the participants were Caucasian. Between
1989 and 2000 the number of VIP participants in the
Umeå region without diabetes type 1 or 2 at the time of
their health examination was 28 736. A study of selec-
tion bias showed small differences between participants
and non-participants [28].
Of all VIP participants examined between 1989 and
2000, 237 were diagnosed with T2DM after their exam-
ination and before January 2001 (Figure 1). T2DM was
diagnosed according to World Health Organisation
(WHO) criteria 1999 [29]. Participants were excluded if
fasting plasma glucose (FPG) levels exceeded 6.9 mmol/L
or 2-hour plasma glucose (2hPG) levels exceeded
12.1 mmol/L (n=11), if the participants had chosen not to
donate blood (n=34), if the samples were prioritized to
other studies (n=25), if data were missing (n=8), or if
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with stored plasma samples and without T2DM accord-
ing to the registry were randomly selected for each case
and matched for sex, age, and year of health examination.
Thus, we included 157 cases with T2DM diagnosis during
follow-up and 277 referents.
Measurements
Body mass index (BMI) was calculated as measured
weight in kilograms divided by the square of the height
in metres (kg/m2). Smoking was categorized into three
groups: non-smokers, ex-smokers, or daily smoking. Par-
ticipants who reported that they smoked irregularly were
categorised as ex-smokers. Participants were considered
to have a family history of diabetes if they reported hav-
ing a parent or sibling with T2DM. Physical activity was
categorised into three levels based on the questionnaire
about self-reported leisure time exercise and commuting
habits during winter, as physical activity during the rest
of the year was presumed to be at least as high as the ac-
tivity during winter: 1) sedentary, never exercise, cycle
and/or walk during their leisure time less than 2–3 times
per month, take bus or car to work, or cycle and/or walk
to work less than 2 km; 2) moderate, exercise now and
then but not regularly or at most once a week, cycle
and/or walk during their leisure time at least 2–3 times
per week, or cycle and/or walk to work 2–5 km; 3) ac-
tive, moderately active person who trains at least 2–3
times/week, or cycle or walk to work more than 5 km.
Hypertension was defined as systolic blood pressure ≥
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg
and/or reported use of antihypertensive medication dur-
ing the 14 days prior to the health examination. Blood
pressure was measured with a mercury sphygmomanom-
eter with the participant in the supine position after a 5-
min rest.
Participants were instructed to fast from midnight
until the time of blood sampling. Venous blood samples
were drawn with minimum stasis in a sitting position
into evacuated glass tubes containing 1/100 volume of
0.5% EDTA. The sample tube was centrifuged at 1500 × g;
the plasma was immediately frozen at −20°C and stored
at −80°C in the Northern Sweden Medical Research
Bank until analysis. Oral glucose tolerance tests
(OGTTs) were performed with a 75-g glucose load
according to WHO standards. Fasting glucose concen-
trations were measured in venous plasma and glucose
concentrations 2 hours after glucose intake in capillary
plasma on a Reflotron bench-top analyser (Boehringer
Mannheim GmbH, Mannheim, Germany). Triglycerides
were analysed in thawed frozen samples via routine
methods at the Department of Clinical Chemistry at
Umeå University Hospital. ELISA reagent kits for tPA
antigen, PAI-1 antigen, and the tPA/PAI-1 complexwere purchased from Biopool (Umeå, Sweden). The
inter-assay coefficients of variation (CVs) were: tPA
10.8%, PAI-1 7.1%, and tPA/PAI-1 complex 8.3%. Re-
agent kits with identical batch numbers were used for
each analysis. The VWF levels were analysed with
reagents purchased from DAKO (Copenhagen, Denmark).
The CV for VWF was 6.5%. CRP was measured with an
automated chemiluminescent immunoassay using the
IMMULITEW analyser from DPC (Los Angeles, CA, USA).
The CV for CRP was 3.8%. All samples were thawed in a
37°C water bath and analysed directly afterward. Samples
from cases and their matched referents were analysed
together in a random order. Measurements were made in
2005 by laboratory staff unaware of each participant’s
disease status. Storage time has been shown to have a
negligible impact on laboratory measurements of frozen
samples [30].Statistical analysis
Data are presented as proportions, means, and standard
deviations (SDs) or median and interquartile range for
cases and referents. Significance was tested using the in-
dependent sample t-test for normally distributed con-
tinuous variables, Mann–Whitney test for non-normally
distributed continuous variables, and chi-squared for
categorical variables.
Conditional logistic regression was used to calculate
age- and sex-matched odds ratios (ORs) comparing the
risk of incident T2DM in cases and referents. Natural
logarithmic transformation was used for CRP, triglycer-
ides, VWF, tPA, PAI-1, and tPA/PAI-1 measurements
because these variables were not normally distributed.
The ORs with 95% confidence intervals (CIs) were cal-
culated per 1 SD increment for continuous variables.
Adjustments were performed for each haemostatic risk
factor and potential confounders in three models with
complete data sets: 1) BMI, smoking, family history of
diabetes, and physical activity; 2) BMI, smoking, CRP,
systolic blood pressure, and triglycerides; and 3) model 2
plus FPG and 2hPG levels.
To investigate whether haemostatic factors deteriorate
prior to the increase in plasma glucose, cases were
divided into two groups: 59 cases with normal glucose
values (FPG <6.1 mmol/L and 2hPG <8.9 mmol/L at
baseline) and their matched referents, and 98 cases with
elevated glucose values (FPG = 6.1-6.9 mmol/L and/or
2hPG = 8.9-12.1 mmol/L at baseline) and their matched
referents. Multivariate conditional logistic regression
was performed for each fibrinolytic factor, BMI, family
history of diabetes, physical activity, smoking, CRP, sys-
tolic blood pressure, and triglycerides. ORs with 95% CIs
were calculated per 1 SD increment for continuous
variables.
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was used for statistical analysis. P- <0.05 (two-sided) was
considered significant.
Ethical considerations
This study protocol was approved by the Research Ethics
Committee of Umeå University. All participants pro-
vided informed consent.
Results
Cases with T2DM were diagnosed a median 5.5 years
(range 0.1-10.6 years) after the baseline health examin-
ation in VIP. The baseline characteristics for cases and
referents are given in Table 1. Cases reported having a
parent or sibling with diabetes more often than refer-
ents. No difference was found in smoking status and
physical activity at baseline. Hypertension was more
common among cases. Cases with incident T2DM had
higher baseline systolic and diastolic blood pressure,
FPG, 2hPG, BMI, and triglyceride, CRP, tPA, PAI-1, tPA/
PAI-1, and VWF levels compared to referents.
The univariate conditional logistic regression analysis
showed a significantly increased risk of incident T2DMTable 1 Baseline characteristics for cases with incident type 2
n Cases
Time to T2DM diagnosis, years 157 5.5 ± 2.7
Age, years 157 50.5 ± 8.1
Sex, male (%) 157 56.7
Family history of T2DM, n (%) 154 48 (31.4)
Non, Ex, Daily smoking, n (%) 156 56 (35.9), 56 (35.9), 44
Sedentary, Moderate, Active, n (%) 157 23 (14.6), 116 (73.9), 1
Hypertension*, n (%) 157 104 (66.2)
Antihypertensive medication, n (%) 157 41 (26.1)
Systolic blood pressure, mmHg 157 139.2 ± 18.3
Diastolic blood pressure, mmHg 157 87.0 ± 12.5
Fasting plasma glucose, mmol/L 157 5.9 ± 0.8
2-h plasma glucose, mmol/L 157 8.2 ± 2.1
BMI, kg/m2 156 29.5 ± 4.2
Total cholesterol, mmol/L 157 6.0 ± 1.0
HDL, mmol/L 157 1.1 ± 0.3
Triglycerides, mmol/L 157 1.7 (1.3 - 2.5)
tPA, ng/mL 156 11.0 (8.7 - 13.7)
PAI-1, ng/mL 157 35.0 (23.9 - 46.1
tPA/PAI-1 complex, ng/mL 155 7.9 (5.2 - 0.4)
VWF, % 156 142.9 (119.1 - 178
Values are mean ± SD for continuous, and percent for non-continuous variables. Me
distribution.
BMI: body mass index; CRP: C-reative protein; T2DM: type 2 diabetes mellitus; tPA: ti
Willebrand factor; SD: standard deviation.for family history of diabetes, hypertension, systolic and
diastolic blood pressure, FPG, 2hPG, BMI, triglycerides,
CRP, tPA, PAI-1, tPA/PAI-1 complex, and VWF
(Table 2). The exclusion of patients taking antihyper-
tensive medication did not affect the association of
haemostatic variables with incident T2DM (data not
shown).
Multivariate regression analysis was performed
for each haemostatic factor (Table 3). In model 1, tPA
(OR = 1.79, 95% CI 1.27-2.53), PAI-1 (OR = 1.86, 95%
CI 1.34-2.59), tPA/PAI-1 complex (OR = 2.92, 95% CI
1.92-4.43), and VWF (OR = 1.43, 95% CI 1.04-1.94) were
independently associated with incident T2DM. In model
2, tPA, PAI-1, and tPA/PAI-1 complex were related to
incident T2DM, but VWF (OR =1.33, 95% CI 0.95-1.85)
was no significantly associated with incident T2DM. In
model 3, only PAI-1 (OR = 1.60, 95% CI 1.03-2.47) and
tPA/PAI-1 (OR = 1.70, 95% CI 1.02-2.82) remained inde-
pendently associated with incident T2DM.
Subgroup analysis
Conditional univariate and multivariate analysis was per-




277 50.2 ± 8.3 matched
277 56.7 matched
269 44 (16.4) < 0.001
(28.2) 272 112 (41.2) 105 (38.6) 55 (20.2) 0.163
8 (11.5) 277 48 (17.3), 190 (68.6), 39 (14.1) 0.507
277 39 (32.1) < 0.001
277 16 (5.8) < 0.001
276 127.5 ± 16.8 < 0.001
276 79.7 ± 10.4 < 0.001
277 5.2 ± 0.7 < 0.001
277 6.5 ± 1.7 < 0.001
277 25.3 ± 3.6 < 0.001
277 5.7 ± 1.0 < 0.001
277 1.3 ± 0.3 0.002
277 1.1 (0.9 - 1.6) < 0.001
276 7.7 (5.6 - 10.5) < 0.001
) 276 21.2 (14.6 - 31.3) < 0.001
277 3.8 (2.5 - 5.8) < 0.001
.9) 276 124.0 (96.0 - 159.6) < 0.001
dian and interquartile range presented for variables not displaying normal
ssue plasminogen activator; PAI-1: plasminogen activator inhibitor-1; VWF: von
Table 2 Risk of incident type 2 diabetes in 157 cases
compared to 277 referents
OR 95% CI p-value
Family history of T2DM 2.46 1.52 - 3.97 < 0.001
Smoking (daily vs non-smoker) 1.69 0.98 - 2.89 0.059
Physical activity (sedentary vs active) 0.94 0.44 - 2.02 0.878
Hypertension* 3.85 2.48 - 5.97 < 0.001
Systolic blood pressure 2.00 1.58 - 2.54 < 0.001
Diastolic blood pressure 1.93 1.51 - 2.47 < 0.001
Fasting plasma glucose 3.77 2.68 - 5.32 < 0.001
2-h plasma glucose 2.65 2.03 - 3.47 < 0.001
BMI 3.09 2.29 - 4.18 < 0.001
Triglycerides 2.38 1.84 - 3.07 < 0.001
CRP 1.91 1.51 - 2.42 < 0.001
tPA 2.63 1.96 - 3.54 < 0.001
PAI-1 2.33 1.79 - 3.03 < 0.001
tPA/PAI-1 complex 4.02 2.84 - 5.69 < 0.001
VWF 1.73 1.36 - 2.19 < 0.001
* Blood pressure ≥ 140/90 and/or on antihypertensive medication.
Conditional logistic regression analysis. OR and 95% CI, per 1 SD increment.
Referents were matched for age and sex. Natural logarithm transformation
was used for haemostatic markers, C-reactive protein and triglycerides.
OR: odds ratio; CI: confidence interval; SD: standard deviation; BMI: body mass
index; CRP: C-reactive protein; T2DM: type 2 diabetes mellitus; tPA: tissue
plasminogen activator; PAI-1: plasminogen activator inhibitor-1; VWF: vn
Willebrand factor.
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baseline (Table 4). Multivariate analysis was carried out
with adjustments for BMI, smoking, family history of
diabetes, physical activity, CRP, systolic blood pressure,
triglycerides, and each haemostatic variable (Figure 2).Table 3 Risk of incident type 2 diabetes mellitus in relation to
Crude OR Multiva
n cases/n referents OR (95% CI) OR
tPA 153/260 2.78
(2.04 - 3.79)§ (1.
PAI-1 152/260 2.35
(1.79 - 3.09)§ (1.
tPA/PAI-1 complex 154/262 4.05
(2.83 - 5.79)§ (1.
VWF 153/261 1.78
(1.39 - 2.29)§ (1.
Conditional logistic regression analysis performed with complete data sets. ORs wit
* Model 1: Adjusted for body mass index, smoking (non/ex/daily smoking), family h
† Model 2: Adjusted for body mass index, smoking (non/ex/daily smoking), family h
protein, systolic blood pressure and triglycerides.
‡ Model 3: Adjusted for body mass index, smoking (non/ex/daily smoking), family h
protein, systolic blood pressure and triglycerides, fasting glucose level and 2 hour c
§ p < 0.05.
Natural logarithm transformation was used for C-reactive protein, triglycerides, tPA,
OR: odds ratio; CI: confidence interval; SD: standard deviation; T2DM: type 2 diabete
inhibitor-1; VWF: von Willebrand factor.As the subgroups were based on normal or elevated glu-
cose levels, no adjustments were made for glucose levels.
For participants with normal glucose levels, all haemo-
static variables were significantly associated with inci-
dent diabetes in the univariate analysis (tPA: OR = 2.43,
95% CI 1.50-3.91; PAI-1: OR=2.66, 95% CI 1.66-4.25;
tPA/PAI-1 complex: OR=3.23, 95% CI 1.93-5.41; VWF:
OR=1.66, 95% CI 1.13-2.46). In multivariate analysis,
only PAI-1 remained significant (OR=2.06, 95% CI 1.10-
3.86). For participants with elevated glucose levels, all
haemostatic variables were significantly associated with
incident diabetes in the univariate analysis (tPA:
OR=3.05, 95% CI 2.02-4.61; PAI-1: OR=2.20, 95% CI
1.57-3.07; tPA/PAI-1 complex: OR=4.80, 95% CI 2.90-
7.92; VWF: OR=1.86, 95% CI 1.35-2.58). After adjust-
ments, tPA (OR=1.82, 95% CI 1.11-2.98) and tPA/PAI-1
complex (OR=4.01, 95% CI 1.90-8.46) remained
significant.
Discussion
This study shows that elevated levels of tPA, PAI-1, and
tPA/PAI-1 complex precede incident diabetes after
adjusting for metabolic and cardiovascular risk factors.
The association of PAI-1 with incident T2DM was also
detected in participants with normal blood glucose levels
at baseline, indicating that fibrinolytic impairment
occurs prior to increased glucose levels.
An earlier study of individuals with normal OGTT
who were followed for 9 years revealed that the 15 parti-
cipants who developed T2DM had significantly higher
tPA antigen levels compared to referents after adjusting
for factors associated with metabolic syndrome [12]. In
this larger study, we found an association between tPAeach haemostatic variable
riate model 1* Multivariate model 2† Multivariate model 3‡
(95% CI) OR (95% CI) OR (95% CI)
1.79 1.54 1.22
27 - 2.53)§ (1.06 - 2.23)§ (0.77 - 1.94)
1.86 1.61 1.60
34 - 2.59)§ (1.14 - 2.28)§ (1.03 - 2.47)§
2.92 2.45 1.70
92 - 4.43)§ (1.56 - 3.84)§ (1.02 - 2.82)§
1.43 1.33 1.33
04 - 1.94)§ (0.95 - 1.85) (0.88 - 2.02)
h 95% CIs, per 1 SD increment.
istory of T2DM and physical activity (sedentary/moderate/active).
istory of T2DM, physical activity (sedentary/moderate/active), C-reactive
istory of T2DM, physical activity (sedentary/moderate/active), C-reactive
apillary glucose level.
PAI-1, tPA/PAI-1 complex and VWF.
s mellitus; tPA: tissue plasminogen activator; PAI-1: plasminogen activator
Table 4 Risk of incident type 2 diabetes mellitus for cases with normal glucose levels* and cases with elevated glucose
levels†
Cases with normal glucose levels* Cases with elevated glucose levels†
Crude OR Multivariate model‡ Crude OR Multivariate model‡
n cases/n referents OR (95% CI) OR (95% CI) n cases/n referents OR (95% CI) OR (95% CI)
tPA 59/103 2.43 1.24 94/157 3.05 1.82
(1.50 - 3.91)§ (0.57 - 2.70) (2.02 - 4.61)§ (1.11 - 2.98)§
PAI-1 57/100 2.66 2.06 95/160 2.20 1.40
(1.66 - 4.25)§ (1.10 - 3.86)§ (1.57 - 3.07)§ (0.89 - 2.20)
tPA/PAI-1 complex 59/103 3.23 1.67 95/159 4.80 4.01
(1.93 - 5.41)§ (0.87 - 3.22) (2.90-7.92)§ (1.90 - 8.46)§
VWF 58/102 1.66 1.43 95/159 1.86 1.35
(1.13 - 2.46)§ (0.79 - 2.59) (1.35 - 2.58)§ (0.87 - 2.09)
* Fasting plasma glucose (FPG) < 6.1 and 2-hour capillary plasma glucose (2hPG) < 8.9 mmol/L.
† FPG 6.1-6.9 and/or 2hPG 8.9-12.1 mmol/L.
Conditional logistic regression analysis performed with complete data sets. ORs with 95% CIs, per 1 SD increment.
‡ Model including body mass index, smoking (non/ex/daily smoking), family history of T2DM, physical activity (sedentary/moderate/active), C-reactive protein,
systolic blood pressure and triglycerides and one of the fibrinolytic variables (tPA: tissue plasminogen activator; PAI-1: plasminogen activator inhibitor-1 or
tPA/PAI-1 complex).
§ p < 0.05.
Natural logarithm transformation was used for C-reactive protein, triglycerides, tPA, PAI-1 and tPA/PAI-1 complex.
OR: odds ratio; CI: confidence interval; SD: standard deviation.
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cardiovascular risk factors. This association disappeared
after additional adjustments were made for FPG and
2hPG. Diabetic patients have active coagulation and
hypofibrinolysis induced by both chronic and acute
hyperglycaemia [6,7]. An experimental investigation has
shown that high glucose levels increase the production
of tPA antigen from human mesengial cells [31], sug-
gesting that the tPA increase found in this study may be
stimulated by glucose.Figure 2 Forest plots illustrating risk for incident type 2 diabetes in A
glucose levels‡. †Fasting plasma glucose (FPG) < 6.1 and 2-hour capillary
12.1 mmol/L. Conditional logistic regression analysis performed with comp
analysis including body mass index, smoking (non/ ex/ daily smoking), fam
C-reactive protein, systolic blood pressure and triglycerides and one of the
plasminogen activator inhibitor-1, tPA/PAI-1 complex) or VWF: von Willebra
protein, triglycerides, tPA, PAI-1 and tPA/PAI-1 complex. OR: odds ratio; CI:Both PAI-1 antigen and the tPA/PAI-1 complex were
significantly associated with incident T2DM in all
three multivariate models. This result is in agreement
with other reports of a relationship between PAI-1
and incident diabetes [18,19] independent of metabolic
syndrome [32]. Visceral adipose tissue has been shown
to increase PAI-1 secretion [33]. In a cross-sectional
study, both tPA and PAI-1 activities and antigens were
associated with metabolic syndrome parameters in
patients with or without T2DM [34]. However, the) cases with normal glucose levels† and B) cases with elevated
plasma glucose (2hPG) < 8.9 mmol/L. ‡ FPG 6.1-6.9 and/or 2hPG 8.9-
lete data sets. ORs with 95% CIs, per increment of 1 SD. Multivariate
ily history of T2DM, physical activity (sedentary/ moderate/ active),
haemostatic variables (tPA: tissue plasminogen activator; PAI-1:
nd Factor. Natural logarithm transformation was used for C-reactive
confidence Interval; SD: standard deviation.
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and other components of the metabolic syndrome.
In participants with normal glucose levels, only PAI-1
remained significantly associated with incident diabetes
in the multivariate analysis. In participants with elevated
glucose levels, only tPA and tPA/PAI-1 complex
remained significantly associated with incident diabetes.
This finding implies that tPA and PAI-1 play different
roles in the pathophysiology of T2DM, with PAI-1 levels
increasing early in the disease. As pre-diabetic changes
develop and blood glucose levels start to increase, tPA
and tPA/PAI-1 complex increase.
The influence of PAI-1 on the development of T2DM
was discussed previously in a variety of contexts. Obesity
has been shown to be associated with chronic inflamma-
tion [35]. CRP has been shown to up-regulate the gene
expression of PAI-1 in human aortic endothelial cells
[36]. Resident macrophages in the adipose tissue pro-
duce cytokines, such as tumour growth factor (TGF)-β
and tumour necrosis factor (TNF)-α, that also up-
regulate PAI-1 [37,38], indicating that the increase in
PAI-1 occurs parallel to the obesity-induced develop-
ment of T2DM. Therefore, the up-regulation of PAI-1
early in the development of T2DM may be seen as a re-
sult of the metabolic syndrome. Mouse models have
raised the possibility that PAI-1 is not merely a product
of obesity, but has a causal role in obesity and insulin re-
sistance, as PAI-1 inhibition has the potential to reduce
obesity and improve insulin sensitivity [39,40], possibly
via PAI-1 functioning as an integrator of cell signalling
[41]. In T2DM patients, PAI-1 antigen levels have been
shown to decrease following metformin treatment [42].
Weight reduction in obese individuals was also asso-
ciated with a decrease in PAI-1 antigen levels [43], which
is explained, in part, by the loss of PAI-1-secreting vis-
ceral adipose tissue [33] but may also be affected by
other PAI-1 functions.
A previous investigation reported no association be-
tween VWF and incident T2DM after adjusting for IL-6,
adiponectin, and γ-glutamyl transferase [13]. In our
study, VWF was associated with T2DM in the univariate
analysis and model 1, but this association was lost after
further adjustments in model 2 for CRP, systolic blood
pressure, and triglycerides. This result is in line with pre-
vious research showing that inflammatory markers can
activate endothelial cells that produce VWF [24].
Strengths and limitations
The major advantage of this study is the prospective
nested case-referent study design within a well-defined
population-based intervention programme, the VIP.
Men and women age 30 to 60 years underwent an ex-
tensive baseline health examination regarding cardiovas-
cular risk factors at their local health centre. Diabeticpatients were defined by FPG and OGTT. Participants
who developed T2DM were examined years before the
manifest diagnosis.
The number of missing cases is high, as 80 of the ori-
ginal 237 cases did not have blood samples available for
laboratory analysis of the haemostatic variables. Baseline
data for 60 cases without blood samples available
showed that no significant difference existed in diastolic
and systolic blood pressure, FPG levels, or BMI com-
pared to the cases in the study. As data on the cases
without blood samples was similar to the data on those
included in the study, selection bias is unlikely. Lifestyle
changes recommended in the initial health examination,
such as weight loss and smoking cessation, may have
influenced the results. In a 10-year follow-up study [44],
VIP participants with baseline glucose intolerance or
T2DM were the most likely to avoid weight gain, but
this occurrence most likely affected the incidence of
T2DM and not the relationship between baseline fi-
brinolytic data and the risk of developing diabetes in a
given individual. The vast majority of participants were
Caucasian, limiting the possibility of generalising the
results to other ethnicities. A risk of regression dilution
bias exists because only a single baseline blood sample
was used, which may decrease the estimations of the
observed associations.
Conclusions
Elevated levels of fibrinolytic variables precede the mani-
festation of T2DM after adjusting for metabolic and car-
diovascular risk factors and can be detected several years
before changes in glucose tolerance
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